 Median Progression-Free Survival of 11.3 months in first-line gastric cancer patients treated with DKN-01 plus tislelizumab and CAPOX, exceeding benchmarks in the overall population and in DKK1 and PD-L1 subgroups Median Overall Survival is not mature with only 44 of patients deceased as of the data cut Enrollment ongoing in the study of DKN-01 plus Tecentriq atezolizumab in second- or third-line oesophagogastric cancer patients, activity in DKK1-high patients consistent with prior studies with pembrolizumab or tislelizumab CAMBRIDGE, Mass. , Sept. 4, 2022 PRNewswire -- Leap Therapeutics, Inc. NASDAQ: LPTX, a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the Company will be presenting data in first-line patients with advanced gastroesophageal adenocarcinoma GEA from the DisTinGuish study, a Phase 2a clinical trial evaluating Leaps anti-Dickkopf-1 DKK1 antibody, DKN-01, in combination with tislelizumab, BeiGenes anti-PD-1 antibody, and chemotherapy, at the European Society for Medical Oncology ESMO Congress 2022 being held on September 9-12. 